Glenmark had in May intimated the research to look at whether or not early administration of a mix of Favipiravir and Umifenovir enhances antiviral efficacy on Covid-19 sufferers.
Announcing the outcomes of its “FAITH” mixture trials, the corporate mentioned that addition of Umifenovir didn’t exhibit any further profit over Favipiravir alone in reasonable Covid-19 sufferers.
“Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment. The trial did not meet key end-points,” it mentioned in a press release.
This was the second scientific research after the Favipiravir monotherapy trial earlier this 12 months that led the corporate to receiving the Emergency Use Authorisation for Favipiravir.
“This second study titled the FAITH trial evaluated the possible superiority of the combination’s efficacy against Favipiravir monotherapy. As per the results that Glenmark today presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir,” it additional mentioned.
The FAITH research enrolled a complete of 158 hospitalized sufferers with reasonable COVID-19 in India.
The Median time to scientific remedy improved by just one day (7 as in comparison with 8) in sufferers who acquired the 2 antiviral mixture. The firm mentioned it was not statistically vital and didn’t justify including two antiviral brokers.
Monika Tandon, Senior Vice President & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals Ltd., mentioned, “Glenmark was the first company to provide patients an oral antiviral treatment for Covid-19 in India, and this combination study was yet another effort on our part to examine new treatment options to combat the health crisis. These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable & effective choice for mild to moderate COVID-19 infection.”